SCHEMBL3601480

SCHEMBL3601480

Cc1ccc(-c2ccc3ccn(CC(=O)NCCN4CC(C)CC(C)C4)c3c2)cc1

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 2/20 0.49
▸ GRIN2B Q13224 5/20 0.43
▸ ALDH1A1 P00352 3/20 0.42
▸ POLB P06746 1/20 0.42
▸ LMNA P02545 2/20 0.41
▸ MTNR1A P48039 4/20 0.40
▸ MTNR1B P49286 4/20 0.40
▸ KDM4E B2RXH2 2/20 0.40
▸ KMT2A Q03164 2/20 0.39
▸ NPC1 O15118 1/20 0.39
▸ HPGD P15428 2/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ CYP3A4 P08684 1/20 0.37
▸ CYP2C9 P11712 1/20 0.37
▸ CYP2C19 P33261 1/20 0.37
▸ NPSR1 Q6W5P4 1/20 0.37
▸ RXFP1 Q9HBX9 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3604427 0.88 GRIN2B (0.45) GRIN2BALDH1A1POLBLMNAMTNR1A
SCHEMBL3605190 0.86 KMT2A (0.49) GRIN2BALDH1A1POLBMTNR1AMTNR1B
SCHEMBL3597719 0.85 KMT2A (0.48) GRIN2BALDH1A1POLBMTNR1AMTNR1B
SCHEMBL3602569 0.85 KMT2A (0.48) GRIN2BALDH1A1POLBMTNR1AMTNR1B
SCHEMBL3597694 0.83 HPGD (0.50) GAAGRIN2BALDH1A1POLBLMNA
SCHEMBL3608056 0.83 GRIN2B (0.41) GRIN2BALDH1A1POLBMTNR1AMTNR1B
SCHEMBL3603236 0.83 POLB (0.55) GAAGRIN2BALDH1A1POLBKDM4E
SCHEMBL3600661 0.82 KDM4E (0.55) GRIN2BALDH1A1POLBLMNAMTNR1A
SCHEMBL3595366 0.80 DRD3 (0.41) GRIN2BALDH1A1KDM4EHPGD
SCHEMBL3594735 0.80 HSD17B10 (0.57) GRIN2BALDH1A1LMNAKDM4EKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7807704-B2 Bicyclic, nitrogen-containing compounds modulating CXCR4 and/or CCXCKR2 CHEMOCENTRYX, INC. (US) 2010-10-05 — — US disclosed
US-7807704-B2 Bicyclic, nitrogen-containing compounds modulating CXCR4 and/or CCXCKR2 CHEMOCENTRYX, INC. (US) 2010-10-05 — — US disclosed
US-7807704-B2 Bicyclic, nitrogen-containing compounds modulating CXCR4 and/or CCXCKR2 CHEMOCENTRYX, INC. (US) 2010-10-05 — — US disclosed
US-20070275965-A1 CXCR4 modulators CHEMOCENTRYX, INC. (US) 2007-11-29 — — US disclosed
US-20070275965-A1 CXCR4 modulators CHEMOCENTRYX, INC. (US) 2007-11-29 — — US disclosed
US-20070275965-A1 CXCR4 modulators CHEMOCENTRYX, INC. (US) 2007-11-29 — — US disclosed
WO-2007115231-A2 CXCR4 MODULATORS CHEMOCENTRYX, INC. (US) 2007-10-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275965-A1 CXCR4 modulators CXCL12, CXCR4, CXCR1 GAA 1982/4885GRIN2B 2950/4885ALDH1A1 662/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback